ArticleClinical rheumatology2026
Clinical characteristics and associated factors of difficult-to-treat rheumatoid arthritis: a cross-sectional study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging therapies for knee osteoarthritis.Nature reviews. Rheumatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThis study aimed to describe the clinical characteristics and explore factors cross-sectionally associated with difficult-to-treat rheumatoid arthritis (D2T RA) in a Chinese population, providing evidence for characterizing the clinical phenotype and identifying current associated factors in a Chinese population.
methodsA cross-sectional study was conducted, enrolling RA patients treated at the Rheumatology Department of Dongfang Hospital, Beijing University of Chinese Medicine, from September 2022 to September 2024. Based on the 2020 EULAR criteria, adapted in accordance with the 2021 Chinese consensus on refractory rheumatoid arthritis, patients were categorized into a D2T RA group (n = 61) and a conventional RA group (n = 182). An exploratory subsample (n = 6 per group) underwent plasma cytokine analysis via Luminex assay. Data on demographics, disease activity measures, laboratory inflammatory parameters, comorbidities, and medication use were collected. Plasma cytokine levels were measured using Luminex technology. Statistical analysis was performed using R software, and associated factors were analyzed via univariate and multivariate logistic regression.
resultsPatients in the D2T RA group were significantly younger than those in the RA group (P = 0.009) and exhibited significantly higher values in swollen joint count, VAS pain score, DAS28-ESR, CDAI, and SDAI (all P < 0.05). The prevalence of osteoporosis was significantly higher in the D2T RA group (85.25% vs. 61.54%, P = 0.001), and the usage of JAK inhibitors was also notably elevated (85.25% vs. 1.10%, P = 0.027). Regarding inflammatory markers, except for elevated plateletcrit, no significant differences were observed in CRP, ESR, IL-6, or composite inflammation indices between groups. Exploratory cytokine analysis (n = 6 per group) showed that IL-6 and IL-17A levels were significantly elevated in the D2T RA group compared to healthy volunteers, whereas no significant differences were observed between the RA and D2T RA groups. Multivariate logistic regression identified that older age was associated with lower odds of D2T RA (OR = 0.94, 95% CI: 0.91-0.98, P = 0.011), while OP remained independently associated with higher odds (OR = 4.95, 95% CI: 1.96-12.15, P < 0.001).
conclusionIn this single-center Chinese cohort, D2T RA was characterized by younger age, higher disease activity, and a higher comorbidity rate of osteoporosis. Younger age and comorbid osteoporosis were cross-sectionally associated with D2T RA. These findings may assist clinicians in recognizing high-risk clinical phenotypes and inform the development of targeted intervention strategies, but require confirmation in prospective, multicenter studies.
Indexed as
Identifiers
42860473What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.